EORTC 2013-BTG

  • Research type

    Research Study

  • Full title

    Observational study for assessing treatment and outcome of patients with primary brain tumours diagnosed according to cIMPACT-NOW recommendations and the 2021 WHO classification

  • IRAS ID

    318611

  • Contact name

    Paul Brennan

  • Contact email

    paul.brennan@ed.ac.uk

  • Sponsor organisation

    European Organisation for the Research and Treatment of Cancer (EORTC)

  • Duration of Study in the UK

    12 years, 0 months, 1 days

  • Research summary

    This observational study is for adults who have brain tumours that have either been diagnosed for the first time or the tumour has come back after treatment.

    The main aims of the study are to create a database to register patients and to provide updated disease profiles including data on age at diagnosis, clinical and imaging (scans) presentation, currently available treatments and outcomes. In order to do this, we will collect data regarding any treatments that have been received since the tumour was diagnosed to see how well patients have responded. This information will be collected from medical notes. If the data is unavailable, the direct care team will collect this directly from the participant during their standard of care visits.

    Additionally, some of the tumour tissue that was taken at diagnosis, and any further tissue that was taken if the tumour comes back will be collected from hospital archives. No additional visits or procedures are required as a result of taking part in this study. Information will be collected over a period of ten years.

    Compared with tumours in other organ sites, brain tumours can be particularly complex, differing significantly in their features, age preference, how they are made-up, their response to therapy, and prognosis. With the rapid evolution of diagnostic methods and the advance of new treatments, there is much less reliable information available in the public domain on how patients should be treated and what clinicians, patients and relatives may expect from the treatments that are currently being administered. The goal of this project is to close this gap of knowledge.

    The study will take place in the NHS in the UK and in several other countries as part of a wider international study.

    The study is sponsored by the European Organisation for Research and Treatment of Cancer (EORTC).

  • REC name

    Wales REC 6

  • REC reference

    23/WA/0188

  • Date of REC Opinion

    31 Jul 2023

  • REC opinion

    Further Information Favourable Opinion